Fundraising Fox

Kodiak Sciences

NASDAQ: KOD

Palo Alto, US · Delaware corporation

kodiak.com ↗

Kodiak Sciences is a biotechnology company developing therapeutics for retinal and ophthalmic diseases, including wet AMD, diabetic retinopathy, retinal vein occlusion, and macular edema. Its Antibody Biopolymer Conjugate Drug (ABCD) platform underpins late-phase candidates such as Zenkuda, KSI-501, and KSI-101.

BiotechMedical Devices

Founders & leadership

JB
John BorgesonExecutive

Reported raises · per SEC filings

Form D private placements

$34M disclosed across 1 round · 2015

▶$34MraisedMar 2016 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John BorgesonExecutive Officer
Offering amount
$34M
Amount sold
$34M
First sale
Sep 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Seeking Alpha49 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.

Companies competing with Kodiak Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Kodiak Sciences do?
Kodiak Sciences is a biotechnology company developing therapeutics for retinal and ophthalmic diseases, including wet AMD, diabetic retinopathy, retinal vein occlusion, and macular edema. Its Antibody Biopolymer Conjugate Drug (ABCD) platform underpins late-phase candidates such as Zenkuda, KSI-501, and KSI-101.
How much funding has Kodiak Sciences raised?
Kodiak Sciences has disclosed $34M raised across 1 round.
Where is Kodiak Sciences headquartered?
Kodiak Sciences is headquartered in Palo Alto, US.